Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Hodgkin Disease × atezolizumab × Clear all

Phase

Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 11 Small Cell Lung Carcinoma 6 Lung Neoplasms 6 Carcinoma, Hepatocellular 6 Breast Neoplasms 6 Urinary Bladder Neoplasms 5 Carcinoma, Transitional Cell 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Neoplasms 4 Neoplasm Metastasis 4 Melanoma 4 Glioblastoma 4 Advanced Solid Tumor 4 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Cancer 2 Small Cell Lung Cancer Extensive Stage 2 Sarcoma 2 Recurrence 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Follicular 2 Leukemia, Myeloid, Acute 2 Gliosarcoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2

Interventions

Cyclophosphamide 17 Etoposide 16 fludarabine phosphate 15 Peripheral Blood Stem Cell Transplantation 14 Rituximab 13 Brentuximab Vedotin 13 fludarabine 11 Whole-Body Irradiation 10 Nivolumab 10 Mycophenolic Acid 10 Melphalan 10 Tacrolimus 9 Filgrastim 9 Bendamustine Hydrochloride 9 Carboplatin 8 Ifosfamide 7 Gemcitabine 7 Cytarabine 7 Cyclosporine 7 Busulfan 7 Doxorubicin 6 Prednisone 5 Everolimus 5 Antilymphocyte Serum 5 pembrolizumab 4 Vinblastine 4 Methotrexate 4 Mesna 4 Granulocyte Colony-Stimulating Factor 4 Carmustine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05300282 2026-01-28

FIL_A-BEGEV

Fondazione Italiana Linfomi - ETS

Phase 1/2 Recruiting

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡